儿童青少年烟草与尼古丁使用预防和戒断的初级保健干预:美国预防服务工作组更新证据报告与系统综述
该更新系统综述纳入24项随机临床试验(N=44 521),评估初级保健相关行为与药物干预对儿童青少年烟草使用预防和戒断的效果。行为干预与对照组相比可降低7至36个月随访时的吸烟启动风险(RR 0.82,95%CI 0.73-0.92),但对已吸烟者的戒断无显著效果,药物干预亦未显示显著获益。
要点
- 行为干预可降低非吸烟儿童青少年7至36个月随访时的吸烟启动风险。
- 行为干预对已吸烟青少年的戒烟无显著效果(RR 0.97,95%CI 0.93-1.01)。
- 药物干预(安非他酮、尼古丁替代)在少数小样本试验中未见显著戒烟获益。
核心结论
- 行为干预可能降低非吸烟儿童青少年吸烟启动的可能性。
- 需要研究识别对已吸烟或使用其他烟草产品的青少年有效的行为干预,并了解药物治疗的有效性。
研究设计与样本
- 系统综述纳入24项随机临床试验,总样本量44 521人。
- 研究对象为初级保健相关的儿童青少年,戒断研究年龄至18岁,预防研究年龄至25岁。
- 干预类型为行为或药物干预,对照为无干预或最小干预(如常规 care、注意力控制、等待名单)。
- 检索数据库包括 Cochrane Central Register of Controlled Trials、Cochrane Database of Systematic Reviews、MEDLINE、PsycINFO 和 EMBASE,检索时间2012年9月1日至2019年6月25日,监测至2020年2月7日。
- 采用随机效应荟萃分析合并研究。
主要发现
- 行为干预与对照相比降低7至36个月随访时吸烟启动风险(13项试验,n=21 700;7.4% vs 9.2%;RR 0.82,95%CI 0.73-0.92)。
- 在吸烟者中,行为干预与对照在戒烟方面无统计学显著差异(9项试验,n=2516;80.7% vs 84.1%继续吸烟;RR 0.97,95%CI 0.93-1.01)。
- 2项安非他酮试验(26周,n=523)和1项尼古丁替代治疗试验(12个月,n=257)均未显示药物对戒烟有显著获益。
- 各1项试验(n=2586和n=1645)未发现干预对健康结局或成人吸烟有有益效应。
- 未发现针对年轻成人的预防试验;少数试验涉及非香烟烟草产品的预防或戒断;无试验评估干预对电子烟使用的影响。
临床怎么用
- 在初级保健中,可考虑对非吸烟儿童青少年实施行为干预以预防吸烟启动。
- 对于已吸烟青少年,现有行为干预和药物干预证据未显示显著戒断效果,需谨慎选择。
局限性
- 药物治疗试验数量少且样本量小。
- 缺乏针对年轻成人的预防试验。
- 少数试验涉及非香烟烟草产品,无试验评估电子烟使用。
- 未发现干预对健康结局或成人吸烟有益的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Interventions to discourage the use of tobacco products (including electronic nicotine delivery systems or e-cigarettes) among children and adolescents may help decrease tobacco-related illness and injury. OBJECTIVE: To update the 2013 review on primary care-relevant interventions for tobacco use prevention and cessation in children and adolescents to inform the US Preventive Services Task Force. DATA SOURCES: The Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, MEDLINE, PsyINFO, and EMBASE (September 1, 2012, to June 25, 2019), with surveillance through February 7, 2020. STUDY SELECTION: Primary care-relevant studies; randomized clinical trials and nonrandomized controlled intervention studies of children and adolescents up to age 18 years for cessation and age 25 years for prevention. Trials comparing behavioral or pharmacological interventions with no or a minimal tobacco use intervention control group (eg, usual care, attention control, wait list) were included. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data and a second investigator checked data abstraction for accuracy. Two investigators independently assessed study quality. Studies were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Tobacco use initiation; tobacco use cessation; health outcomes; harms. RESULTS: Twenty-four randomized clinical trials (N = 44 521) met inclusion criteria. Behavioral interventions were associated with decreased likelihood of cigarette smoking initiation compared with control interventions at 7 to 36 months' follow-up (13 trials, n = 21 700; 7.4% vs 9.2%; relative risk [RR], 0.82 [95% CI, 0.73-0.92]). There was no statistically significant difference between behavioral interventions and controls in smoking cessation when trials were restricted to smokers (9 trials, n = 2516; 80.7% vs 84.1% continued smoking; RR, 0.97 [95% CI, 0.93-1.01]). There were no significant benefits of medication on likelihood of smoking cessation in 2 trials of bupropion at 26 weeks (n = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacement therapy at 12 months (n = 257; 8.1% vs 8.2%). One trial each (n = 2586 and n = 1645) found no beneficial intervention effect on health outcomes or on adult smoking. No trials of prevention in young adults were identified. Few trials addressed prevention or cessation of tobacco products other than cigarettes; no trials evaluated effects of interventions on e-cigarette use. There were few trials of pharmacotherapy, and they had small sample sizes. CONCLUSIONS AND RELEVANCE: Behavioral interventions may reduce the likelihood of smoking initiation in nonsmoking children and adolescents. Research is needed to identify effective behavioral interventions for adolescents who smoke cigarettes or who use other tobacco products and to understand the effectiveness of pharmacotherapy.
引用
- Selph S, Patnode C, Bailey SR, et al. Primary Care-Relevant Interventions for Tobacco and Nicotine Use Prevention and Cessation in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020. PMID: 32343335. doi:10.1001/jama.2020.3332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。